AADI Stock Summary and Trading Ideas (Aadi Bioscience | NASDAQ:AADI)

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Aadi Bioscience trades on the NASDAQ stock market under the symbol AADI.

As of September 25, 2023, AADI stock price climbed to $5.01 with 78,877 million shares trading.

AADI has a beta of 0.46, meaning it tends to be less sensitive to market movements. AADI has a correlation of 0.02 to the broad based SPY ETF.

AADI has a market cap of $122.84 million. This is considered a Micro Cap stock.

Last quarter Aadi Bioscience reported $6 million in Revenue and -$.67 earnings per share. This beat revenue expectation by $2,000 and missed earnings estimates by -$.05.

The top ETF exchange traded funds that AADI belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

AADI has underperformed the market in the last year with a return of -59.2%, while the SPY ETF gained +17.2%. In the last 3 month period, AADI fell short of the market, returning -36.1%, while SPY returned -0.6%. However, in the most recent 2 weeks AADI has outperformed the stock market by returning -2.3%, while SPY returned -2.6%.

AADI support price is $4.73 and resistance is $5.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AADI stock will trade within this expected range on the day.